AceLink Therapeutics is involved in drug development, focusing on glycolipid biology and rare genetic diseases. The company collaborates with contract research organizations and academic leaders to transform scientific discoveries into therapies.

AceLink Therapeutics

AceLink Therapeutics | 437 followers on LinkedIn. Overcome genetic diseases, one at a time | AceLink Therapeutics is a startup biopharmaceutical company located in the San Francisco Bay Area. Our mission is to develop first-in-class and best-in-class drugs for genetically associated human diseases with the initial focus on a small molecule drug for polycystic kidney disease (PKD), a human genetic disease with 12 million patients worldwide.

Yuqiao (Jerry) Shen

VP, Research & Early Development at AceLink Therapeutics

Michael Babcock

VP, Operation at AceLink Therapeutics Inc

Li Li

凯泰资本Kaitai Capital - Partner

Xian Li

CrUX Dataset

CrUX Top 50m

Japanese Yen

Vice President, Research & Early Development

Director of Business Development, International Sales

Thomas Mi

Director of Medicinal Chemistry

Yeyu Cao

VP Operations

Bo Liu

Chief Business Officer

Grant Campany

VP, Operation

Chief Medical Officer

Pedro Huertas

VP R&D, Architectural Designer (Concept, Optical, Mechanical Design, Module Development )

Rong Huang

Thaminda Ramanayake

Head of Business Strategy

Kaitai Capital Portfolio Companies

Viva BioInnovator Portfolio Companies

Silicon Valley Companies With Fewer Than 1000 Employees (Top 10K)

Silicon Valley Companies (Top 10K)

AceLink Therapeutics is a startup biopharmaceutical company located in the San Francisco Bay Area.

Venture Round - AceLink Therapeutics

Newark

California

United States

North America

Acelink Therapeutics patents new Keap1/Nrf2 interaction inhibitors

AceLink Therapeutics Appoints Pedro Huertas, M.D., Ph.D., as Chief Medical Officer

Pakistan

Asia

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 21, 2024 6:18 AM	beec3f6c
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 21, 2024 6:18 AM	0808b363
crunchbase trigger	general	Nov 21, 2024 6:18 AM	c2ccfb4a
crunchbase profile	general	Nov 21, 2024 7:24 AM	2faacb88
li profile	general	Nov 21, 2024 6:18 AM	5e434112
translate crunchbase fundingrounds	general	Nov 21, 2024 7:40 AM	c49f2369
peers	general	Nov 21, 2024 6:18 AM	32fda2e6
news basic	general	Nov 21, 2024 6:18 AM	64d7ba2b
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

ACEL

COM:ACELINKTHERAPEUTICS

AceLink Therapeutics